Helus Pharma Inc. has announced that its Chief Executive Officer, Michael Halstead, will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference. This event is scheduled for November 9, 2026, at 3:00 p.m. EDT and will be webcast live.

This participation is significant for Helus Pharma as it showcases the company's commitment to advancing mental health treatment through its innovative serotonergic agonists. The conference provides a platform for Helus to enhance its visibility and connect with industry peers, investors, and stakeholders.

Background

Helus Pharma Inc., listed on Nasdaq under the ticker HELP, operates within the pharmaceutical preparations industry (SIC 2834). The company is dedicated to improving mental health treatment options through the development of novel serotonergic agonists. Recent filings indicate that Helus Pharma is in the clinical stage of developing its proprietary drugs, including HLP003 and HLP004, aimed at treating major depressive disorder and generalized anxiety disorder, respectively.

What the Filing Says

In the recent filing dated November 3, 2026, Helus Pharma confirmed the participation of CEO Michael Halstead in the conference. The filing states, "CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT." This highlights the company's ongoing efforts to engage with the healthcare community and promote its innovative solutions.

Impact

This announcement may affect various stakeholders, including investors, healthcare professionals, and patients seeking new treatment options for mental health conditions. The participation in the conference could potentially lead to increased interest and investment in Helus Pharma's clinical programs and innovations.

What's Next

Following the conference, Helus Pharma may provide updates on its projects and developments. The filing does not specify what happens next, but the company's ongoing clinical trials and research initiatives are expected to continue.